Semaglutide raised it by 7.8 points more than placebo in STEP-HFpEF, and tirzepatide by 6.9 points more in SUMMIT, both measured after 52 weeks of treatment.1,2
What it measures
The KCCQ is a patient-reported outcome: people answer questions about their own symptoms, function and quality of life. The clinical summary score is the part used in these trials, which define it as a score from 0 to 100 in which higher means fewer symptoms and physical limitations.1,2
A 2020 review of the questionnaire explains why it carries weight. The U.S. Food and Drug Administration has qualified the KCCQ as a clinical outcome assessment, and it has been recommended as a measure of the quality of heart failure care. Because it asks the same questions in the same way over time, it captures the impact of heart failure on people's lives reliably, and its scores are strongly associated with later clinical events.3 The review's lead author owns the copyright to the questionnaire, and the review says so.3
Why these trials used it
The authors of STEP-HFpEF note that heart failure with preserved ejection fraction is becoming more common. It carries a heavy burden of symptoms and limited function, especially in people with obesity, and no therapy had been approved to target its obesity-related form when the trial was published in 2023.1 A measure of symptoms and function was therefore a natural main outcome, set alongside weight in STEP-HFpEF and alongside heart failure events in SUMMIT.1,2
In the GLP-1 trials
| Trial | Drug | KCCQ-CSS change, drug | Change, placebo | Difference |
|---|---|---|---|---|
| STEP-HFpEF, 52 weeks | Semaglutide 2.4 mg | +16.6 | +8.7 | 7.8 |
| SUMMIT, 52 weeks | Tirzepatide up to 15 mg | +19.5 | +12.7 | 6.9 |
Kosiborod et al., 2023; Packer et al., 2025.1,2
In both trials the score also rose on placebo, by 8.7 and 12.7 points.1,2 That is why the difference from placebo, not the raw change on the drug, is the number to read: 7.8 points for semaglutide and 6.9 for tirzepatide. The two trials enrolled similar people, those with heart failure with preserved ejection fraction and obesity, but they were run separately and were not designed to compare the drugs.
Alongside other measures
Each trial paired the score with harder measures. In STEP-HFpEF, the 6-minute walk distance rose by 21.5 meters on semaglutide against 1.2 meters on placebo, and serious adverse events were reported by 13.3% against 26.7%.1 SUMMIT counted events: cardiovascular death or worsening heart failure occurred in 9.9% on tirzepatide against 15.3% on placebo.2 Worsening heart failure events on their own occurred in 8.0% against 14.2%.2 STEP-HFpEF also found C-reactive protein, a marker of inflammation, down by 43.5% on semaglutide against 7.3% on placebo, and weight down by 13.3% against 2.6%.1 The symptom score and the harder measures pointed the same way in both trials.
On the labels
Neither Wegovy nor Zepbound lists heart failure with preserved ejection fraction as a separate approved use in the label versions we read.4,5 People with the condition who take either medicine do so under the weight or heart-risk indications, and their prescribers may use the KCCQ to follow how they feel. Our page on Mounjaro and Zepbound explains the approved uses of tirzepatide.
Sources
- Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity (STEP-HFpEF). N Engl J Med 2023;389:1069-1084. doi:10.1056/NEJMoa2306963
- Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity (SUMMIT). N Engl J Med 2025;392:427-437. doi:10.1056/NEJMoa2410027
- Spertus JA, Jones PG, Sandhu AT, Arnold SV. Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC state-of-the-art review. J Am Coll Cardiol 2020;76:2379-2390. doi:10.1016/j.jacc.2020.09.542
- WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; section 1. accessdata.fda.gov
- ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; section 1. accessdata.fda.gov
Related analyses
Mounjaro vs Zepbound: the same drug under two labels, compared by use, results and price
Ozempic vs Wegovy: the same drug under two labels, compared by dose, results and price
Wegovy weight loss chart: the trial results week by week, in your own weight
Zepbound side effects timeline: when they start, how long they last, when they ease
Log how you feel and what you can do each week, alongside your doses.
Open Dose Insider